DE20104684U1 - Medicines used to treat bovine spongiform encephalopathy (BSE) - Google Patents

Medicines used to treat bovine spongiform encephalopathy (BSE)

Info

Publication number
DE20104684U1
DE20104684U1 DE20104684U DE20104684U DE20104684U1 DE 20104684 U1 DE20104684 U1 DE 20104684U1 DE 20104684 U DE20104684 U DE 20104684U DE 20104684 U DE20104684 U DE 20104684U DE 20104684 U1 DE20104684 U1 DE 20104684U1
Authority
DE
Germany
Prior art keywords
medicament according
drug
potentiation
degree
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE20104684U
Other languages
German (de)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALAGNA MEGAL ANGELIKA
Original Assignee
ALAGNA MEGAL ANGELIKA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALAGNA MEGAL ANGELIKA filed Critical ALAGNA MEGAL ANGELIKA
Priority to DE20104684U priority Critical patent/DE20104684U1/en
Publication of DE20104684U1 publication Critical patent/DE20104684U1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßtThe description text was not recorded electronically

Claims (11)

1. Arzneimittel, gekennzeichnet durch einen Gehalt an Farina animale carbonata als Wirkstoff neben üblichen Trägerstoffen, Hilfsmitteln und/oder Zusatzstoffen.1. Medicament, characterized by a content of Farina animale carbonata as an active ingredient in addition to conventional carriers, auxiliaries and / or additives. 2. Arzneimittel nach Anspruch 1, dadurch gekennzeichnet, dass der Anteil von Farina animale carbonata an 10 g Arzneimittel 0,05-0,2 g im Poten­ zierungsgrad D6 beträgt.2. Medicament according to claim 1, characterized in that the proportion of Farina animale carbonata in 10 g of drug 0.05-0.2 g in the pot degree of ornamentation D6. 3. Arzneimittel nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass es neben Farina animale carbonata Luesinum und/oder Pyrogenium als Wirkstoffe enthält neben üblichen Trägerstoffen, Hilfsmitteln und/oder Zusatzstoffen.3. Medicament according to claim 1 or 2, characterized in that it in addition to Farina animale carbonata Luesinum and / or Pyrogenium as active ingredients contains in addition to conventional carriers, auxiliaries and / or additives. 4. Arzneimittel nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass es Lophophytum leandri und/oder Lytta vesicatoria und/oder Okoubaka enthält.4. Medicament according to one of claims 1 to 3, characterized in that it contains Lophophytum leandri and / or Lytta vesicatoria and / or Okoubaka. 5. Arzneimittel nach mindestens einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, dass 10 g Arzneimittel 0,05-0,2 g Luesinum im Potenzierungsgrad C1000 enthalten.5. Medicament according to at least one of claims 1 to 4, characterized in that 10 g of medicinal product contain 0.05-0.2 g of Luesinum in the potentiation level C1000. 6. Arzneimittel nach Anspruch 5. dadurch gekennzeichnet, dass der Potenzierungsgrad von Luesinum D200 oder P20 beträgt. 6. Medicament according to claim 5, characterized in that the degree of potentiation of Luesinum D200 or P20 is.   7. Arzneimittel nach mindestens einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, dass 10 g Arzneimittel 0,05-0,2 g Pyrogenium im Potenzierungsgrad C100 enthalten.7. Medicament according to at least one of claims 1 to 4, characterized in that Contain 10 g of drug 0.05-0.2 g of pyrogenium in the degree of potentiation C100. 8. Arzneimittel nach Anspruch 7, dadurch gekennzeichnet, dass der Potenzierungsgrad von Pyrogenium D200 oder D20 beträgt.8. Medicament according to claim 7, characterized in that the degree of potentiation of Pyrogenium is D200 or D20. 9. Arzneimittel nach Anspruch 4, dadurch gekennzeichnet, dass 10 g Arzneimittel 0,05-0,2 g Lophophytum leandri im Potenzierungsgrad D6 ent­ halten.9. Medicament according to claim 4, characterized in that 10 g of drug 0.05-0.2 g of Lophophytum leandri in potency grade D6 ent hold. 10. Arzneimittel nach Anspruch 4, dadurch gekennzeichnet, dass 10 g Arzneimittel 0,05-0,2 g Lytta vesicatoria im Potenzierungsgrad D6 enthalten.10. Medicament according to claim 4, characterized in that 10 g of medicinal products contain 0.05-0.2 g of Lytta vesicatoria in potency grade D6. 11. Arzneimittel nach Anspruch 4, dadurch gekennzeichnet, dass 10 g Arzneimittel 0,05-0,2 g Okoubaka im Potenzierungsgrad D3 enthalten.11. Medicament according to claim 4, characterized in that Contain 10 g of drug 0.05-0.2 g of Okoubaka in potency grade D3.
DE20104684U 2001-03-14 2001-03-14 Medicines used to treat bovine spongiform encephalopathy (BSE) Expired - Lifetime DE20104684U1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE20104684U DE20104684U1 (en) 2001-03-14 2001-03-14 Medicines used to treat bovine spongiform encephalopathy (BSE)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE20104684U DE20104684U1 (en) 2001-03-14 2001-03-14 Medicines used to treat bovine spongiform encephalopathy (BSE)

Publications (1)

Publication Number Publication Date
DE20104684U1 true DE20104684U1 (en) 2001-06-28

Family

ID=7954474

Family Applications (1)

Application Number Title Priority Date Filing Date
DE20104684U Expired - Lifetime DE20104684U1 (en) 2001-03-14 2001-03-14 Medicines used to treat bovine spongiform encephalopathy (BSE)

Country Status (1)

Country Link
DE (1) DE20104684U1 (en)

Similar Documents

Publication Publication Date Title
ATE212223T1 (en) USE OF SERTRALINE FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE DISEASES
KR840003414A (en) Pharmaceutical compositions containing 3-hydroxybutanoic acid or salts derived from these acids, and compounds derived from 3-hydroxybutanoic acid that can be used as pharmaceuticals
BR0213124A (en) Feed including actives and methods of use
DE20104684U1 (en) Medicines used to treat bovine spongiform encephalopathy (BSE)
ATE205399T1 (en) A STORAGE-Stable AQUEOUS INFUSION SOLUTION CONTAINING A THROMBIN INHIBITOR
RU94017849A (en) Medicinal preparation for neurocorrection
CA2140010A1 (en) Blood coagulation normalizer containing tcf-ii as active ingredient
DE69424679D1 (en) COMPOSITION FOR TREATING OR PREVENTING HERPES
DE68916651T2 (en) MEDICINES FOR TREATING TOXOPLASMOSIS.
ATE107504T1 (en) MEDICATIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS.
DE69312297D1 (en) USE OF 2- [4 - (- CHLOROPHENYL) CYCLOHEXYL] -3-HYDROXY-1,4-NAPHTOQUINONE FOR THE TREATMENT OF CANCER
KR20230090187A (en) Pharmaceutical composite formulation for treating vascular dementia with alzheimer's disease
DE2908127A1 (en) USE OF ENKEPHALINES AND ENDORPHINES INHIBITORS IN THE CONTROL OF PAIN, AND IN THE MANUFACTURING OF PHARMACEUTICAL PREPARATIONS AND MEDICINAL PRODUCTS
KR20220083020A (en) Pharmaceutical composite formulation for treating vascular dementia with alzheimer's disease
KR20220085086A (en) Pharmaceutical composite formulation for treating metabolic syndrome with hypothyroidism
DE3909962A1 (en) Composition for treating plants with wounded (damaged) tissue and for grafting trees and shrubs, containing natural essential oils
JPH04338337A (en) Antidermatomycotic agent
US20030091650A1 (en) Ratite oil as a topical adjuvant and transdermal carrier
JPH04178331A (en) New therapeutic agent for athlete's foot
US20100310545A1 (en) Dry treatment mixture and methods of production and use
Ji et al. Another view of the therapy of leprosy]
WO2014060501A1 (en) Agent for alleviating or treating migraine pain
ES2179520T3 (en) PHARMACEUTICAL USE OF THE CYPRESS.
DE20005402U1 (en) External treatment for skin redness and psoriasis
RU93046236A (en) COMPOSITION FOR THE DESTRUCTION OF TARACANES

Legal Events

Date Code Title Description
R207 Utility model specification

Effective date: 20010802

R150 Term of protection extended to 6 years

Effective date: 20050126

R157 Lapse of ip right after 6 years

Effective date: 20071113